Phase 2 ASPEN-06 data showed higher response rates with evorpacept added to trastuzumab, ramucirumab, and paclitaxel in ...

The 10-year results from the phase 3 CHN HYPOPMRT trial (NCT00793962) showed that hypofractionated postmastectomy radiotherapy (PMRT) delivered over 3 weeks maintained durable locoregional control ...

Jyoti Malhotra, MD, MPH on first-in-human clinical trials, lung cancer precision medicine in 2026, the disparities tension in drug development, and her move to Yale Cancer Center. In this episode ...

Ayal Aizer, MD, MHS, says Alliance A071801 supports fractionated SRS as standard after resection, with comparable radiation necrosis rates. In an interview with CancerNetwork®, Ayal Aizer, MD, MHS, ...

The FDA cleared the SpaceOAR Flex System, a hydrogel spacer used during prostate cancer radiotherapy, in a 510 (k) supported by the HYDROSPACE trial.

Treatment options for patients with relapsed/refractory follicular lymphoma have expanded rapidly. CD19-directed CAR T-cell therapies are approved in the third-line setting and beyond, and CD20 x CD3 ...

Ethan B. Ludmir, MD, details which cholangiocarcinoma subsets, by tumor location, may benefit most from neoadjuvant radiation before surgery.

McFarland, DO, spoke with Yesne Alici, MD, who oversees Memorial Sloan Kettering Cancer Center (MSKCC)’s medical aid in dying (M ...

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD. Meletios A. Dimopoulos, MD, explored how ...

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG ...

Ethan B. Ludmir, MD, explains the rationale for moving radiation into the neoadjuvant setting for borderline resectable ...

Ola Landgren, MD, PhD, discusses how MRD-driven strategies may eliminate the transplant-eligible vs transplant-ineligible ...